Advertisement
Home »

AEGIS-II: Negative Primary Endpoint but Infusions Might Benefit Subgroups of Patients

Apr 26, 2024

REFERENCES & ADDITIONAL READING

Michael Gibson C, Korjian S, Tricoci P, et al. Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). Circulation. 2016;134(24):1918-1930. doi:10.1161/CIRCULATIONAHA.116.025687

Gibson CM, et al. CSL112 (Apolipoprotein A-I) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-I Event Reducing In Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results. LB1, Session 402. Presented at: ACC 2024 Scientific Session, April, 6–8, 2024, Atlanta, GA.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement